

Lung Adenocarcinoma Treatment Market Size, Share & Trends Analysis Report By Treatment (Chemotherapy, Immunotherapy, Radiation Therapy), By End-use (Hospitals, Specialty Clinics), By Region (North America, Europe), And Segment Forecasts, 2025 - 2030

<https://marketpublishers.com/r/L5E47BD0C4CCEN.html>

Date: February 2025

Pages: 100

Price: US\$ 5,950.00 (Single User License)

ID: L5E47BD0C4CCEN

Abstracts

This report can be delivered to the clients within 2 Business Days

Lung Adenocarcinoma Treatment Market Growth & Trends

The global lung adenocarcinoma treatment market size is expected to reach USD 11.18 billion by 2030, registering a CAGR of 10.7% from 2025 to 2030, according to a new report by Grand View Research, Inc. This market offers a range of therapeutic options, technologies, and services aimed at managing and treating lung adenocarcinoma, which is a subtype of non-small cell lung cancer (NSCLC).

The rise in smoking rates in certain regions and environmental factors such as air pollution and occupational hazards are key growth drivers for market growth. As more individuals are diagnosed with lung adenocarcinoma, there is a corresponding demand for effective treatment options.

Increased awareness about lung cancer symptoms and risk factors has significantly influenced the market. Public health campaigns aimed at educating populations about smoking cessation and early detection led to more individuals seeking medical attention sooner after experiencing symptoms.

In October 2023, Bristol Myers Squibb acquired Mirati for USD 58.00 per share, totaling USD 4.8 billion in equity value, potentially rising to USD 5.8 billion with contingent value rights, including KRAZATI (adagrasib), a KRASG12C inhibitor for advanced non-small cell lung cancer.

Lung Adenocarcinoma Treatment Market Report Highlights

The chemotherapy segment accounted for the largest revenue share of 36% in 2024. This is primarily due to its established role in lung cancer management and ongoing advancements in treatment regimens.

The immunotherapy segment is expected to witness the fastest growth, with a projected CAGR of 13.5% over the forecast period. The rising prevalence of lung adenocarcinoma has increased the demand for advanced treatment options that offer better efficacy and safety compared to traditional therapies such as chemotherapy and radiation.

Hospitals accounted for the largest revenue share of 63.9% in 2024, driven by their comprehensive infrastructure and ability to provide a wide range of advanced cancer treatments.

The specialty clinics segment is expected to grow at the fastest CAGR over the forecast period. This growth is driven by the rising demand for personalized and targeted therapies, along with increasing patient awareness of lung cancer treatment options.

North America lung adenocarcinoma treatment market held the largest revenue share of 39.5% in 2024, driven by the rising incidence of lung adenocarcinoma and a strong focus on innovation in treatment approaches.

Contents

CHAPTER 1. METHODOLOGY AND SCOPE

- 1.1. Market Segmentation & Scope
- 1.2. Segment Definitions
 - 1.2.1. Treatment
 - 1.2.2. End use
- 1.3. Estimates and Forecast Timeline
- 1.4. Research Methodology
- 1.5. Information Procurement
 - 1.5.1. Purchased Database
 - 1.5.2. GVR's Internal Database
 - 1.5.3. Secondary Sources
 - 1.5.4. Primary Research
- 1.6. Information Analysis
 - 1.6.1. Data Analysis Models
- 1.7. Market Formulation & Data Visualization
- 1.8. Model Details
 - 1.8.1. Commodity Flow Analysis
- 1.9. List of Secondary Sources
- 1.10. Objectives

CHAPTER 2. EXECUTIVE SUMMARY

- 2.1. Market Snapshot
- 2.2. Segment Snapshot
- 2.3. Competitive Landscape Snapshot

CHAPTER 3. LUNG ADENOCARCINOMA TREATMENT MARKET VARIABLES, TRENDS, & SCOPE

- 3.1. Market Lineage Outlook
- 3.2. Market Dynamics
 - 3.2.1. Market Driver Analysis
 - 3.2.2. Market Restraint Analysis
- 3.3. Business Environment Analysis
 - 3.3.1. Analysis - Porter's Five Forces Analysis
 - 3.3.1.1. Supplier Power

- 3.3.1.2. Buyer Power
- 3.3.1.3. Substitution Threat
- 3.3.1.4. Threat of New Entrants
- 3.3.1.5. Competitive Rivalry
- 3.3.2. PESTLE Analysis
- 3.3.3. Pipeline Analysis

CHAPTER 4. LUNG ADENOCARCINOMA TREATMENT MARKET: TYPE BUSINESS ANALYSIS

- 4.1. Treatment Market Share, 2024 & 2030
- 4.2. Treatment Segment Dashboard
- 4.3. Market Size & Forecasts and Trend Analysis, by Treatment, 2018 to 2030 (USD Million)
- 4.4. Chemotherapy
 - 4.4.1. Chemotherapy Market, 2018 - 2030 (USD Million)
- 4.5. Targeted therapy
 - 4.5.1. Targeted Therapy Market, 2018 - 2030 (USD Million)
- 4.6. Immunotherapy
 - 4.6.1. Immunotherapy Market, 2018 - 2030 (USD Million)
- 4.7. Radiation therapy
 - 4.7.1. Radiation Therapy Market, 2018 - 2030 (USD Million)
- 4.8. Other
 - 4.8.1. Other Market, 2018 - 2030 (USD Million)

CHAPTER 5. LUNG ADENOCARCINOMA TREATMENT MARKET: END USE BUSINESS ANALYSIS

- 5.1. End Use Market Share, 2024 & 2030
- 5.2. End Use Segment Dashboard
- 5.3. Market Size & Forecasts and Trend Analysis, by End Use, 2018 to 2030 (USD Million)
- 5.4. Hospitals
 - 5.4.1. Hospitals Market, 2018 - 2030 (USD Million)
- 5.5. Specialty Clinics
 - 5.5.1. Specialty Clinics Market, 2018 - 2030 (USD Million)
- 5.6. Other
 - 5.6.1. Other Market, 2018 - 2030 (USD Million)

CHAPTER 6. LUNG ADENOCARCINOMA TREATMENT MARKET: REGIONAL ESTIMATES & TREND ANALYSIS

6.1. Regional Market Share Analysis, 2024 & 2030

6.2. Regional Market Dashboard

6.3. Market Size & Forecasts Trend Analysis, 2018 to 2030

6.4. North America

6.4.1. North America Lung Adenocarcinoma Treatment Market Estimates And Forecasts, By Country, 2018 - 2030 (USD Million)

6.4.2. U.S.

6.4.2.1. Key Country Dynamics

6.4.2.2. Regulatory Framework

6.4.2.3. Competitive Insights

6.4.2.4. U.S. Lung Adenocarcinoma Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)

6.4.3. Canada

6.4.3.1. Key Country Dynamics

6.4.3.2. Regulatory Framework

6.4.3.3. Competitive Insights

6.4.3.4. Canada Lung Adenocarcinoma Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)

6.4.4. Mexico

6.4.4.1. Key Country Dynamics

6.4.4.2. Regulatory Framework

6.4.4.3. Competitive Insights

6.4.4.4. Mexico Lung Adenocarcinoma Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)

6.5. Europe

6.5.1. Europe Lung Adenocarcinoma Treatment Market Estimates And Forecasts, By Country, 2018 - 2030 (USD Million)

6.5.2. UK

6.5.2.1. Key Country Dynamics

6.5.2.2. Regulatory Framework

6.5.2.3. Competitive Insights

6.5.2.4. UK Lung Adenocarcinoma Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)

6.5.3. Germany

6.5.3.1. Key Country Dynamics

6.5.3.2. Regulatory Framework

6.5.3.3. Competitive Insights

6.5.3.4. Germany Lung Adenocarcinoma Treatment Market Estimates And Forecasts,
2018 - 2030 (USD Million)

6.5.4. France

6.5.4.1. Key Country Dynamics

6.5.4.2. Regulatory Framework

6.5.4.3. Competitive Insights

6.5.4.4. France Lung Adenocarcinoma Treatment Market Estimates And Forecasts,
2018 - 2030 (USD Million)

6.5.5. Italy

6.5.5.1. Key Country Dynamics

6.5.5.2. Regulatory Framework

6.5.5.3. Competitive Insights

6.5.5.4. Italy Lung Adenocarcinoma Treatment Market Estimates And Forecasts,
2018 - 2030 (USD Million)

6.5.6. Spain

6.5.6.1. Key Country Dynamics

6.5.6.2. Regulatory Framework

6.5.6.3. Competitive Insights

6.5.6.4. Spain Lung Adenocarcinoma Treatment Market Estimates And Forecasts,
2018 - 2030 (USD Million)

6.5.7. Norway

6.5.7.1. Key Country Dynamics

6.5.7.2. Regulatory Framework

6.5.7.3. Competitive Insights

6.5.7.4. Norway Lung Adenocarcinoma Treatment Market Estimates And Forecasts,
2018 - 2030 (USD Million)

6.5.8. Denmark

6.5.8.1. Key Country Dynamics

6.5.8.2. Regulatory Framework

6.5.8.3. Competitive Insights

6.5.8.4. Denmark Lung Adenocarcinoma Treatment Market Estimates And Forecasts,
2018 - 2030 (USD Million)

6.5.9. Sweden

6.5.9.1. Key Country Dynamics

6.5.9.2. Regulatory Framework

6.5.9.3. Competitive Insights

6.5.9.4. Sweden Lung Adenocarcinoma Treatment Market Estimates And Forecasts,
2018 - 2030 (USD Million)

6.6. Asia Pacific

6.6.1. Asia Pacific Lung Adenocarcinoma Treatment Market Estimates And Forecasts, By Country, 2018 - 2030 (USD Million)

6.6.2. Japan

6.6.2.1. Key Country Dynamics

6.6.2.2. Regulatory Framework

6.6.2.3. Competitive Insights

6.6.2.4. Japan Lung Adenocarcinoma Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)

6.6.3. China

6.6.3.1. Key Country Dynamics

6.6.3.2. Regulatory Framework

6.6.3.3. Competitive Insights

6.6.3.4. China Lung Adenocarcinoma Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)

6.6.4. India

6.6.4.1. Key Country Dynamics

6.6.4.2. Regulatory Framework

6.6.4.3. Competitive Insights

6.6.4.4. India Lung Adenocarcinoma Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)

6.6.5. South Korea

6.6.5.1. Key Country Dynamics

6.6.5.2. Regulatory Framework

6.6.5.3. Competitive Insights

6.6.5.4. South Korea Lung Adenocarcinoma Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)

6.6.6. Australia

6.6.6.1. Key Country Dynamics

6.6.6.2. Regulatory Framework

6.6.6.3. Competitive Insights

6.6.6.4. Australia Lung Adenocarcinoma Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)

6.6.7. Thailand

6.6.7.1. Key Country Dynamics

6.6.7.2. Regulatory Framework

6.6.7.3. Competitive Insights

6.6.7.4. Thailand Lung Adenocarcinoma Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)

6.7. Latin America

6.7.1. Latin America Lung Adenocarcinoma Treatment Market Estimates And Forecasts, By Country, 2018 - 2030 (USD Million)

6.7.2. Brazil

6.7.2.1. Key Country Dynamics

6.7.2.2. Regulatory Framework

6.7.2.3. Competitive Insights

6.7.2.4. Brazil Lung Adenocarcinoma Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)

6.7.3. Argentina

6.7.3.1. Key Country Dynamics

6.7.3.2. Regulatory Framework

6.7.3.3. Competitive Insights

6.7.3.4. Argentina Lung Adenocarcinoma Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)

6.8. MEA

6.8.1. MEA Lung Adenocarcinoma Treatment Market Estimates And Forecasts, By Country, 2018 - 2030 (USD Million)

6.8.2. South Africa

6.8.2.1. Key Country Dynamics

6.8.2.2. Regulatory Framework

6.8.2.3. Competitive Insights

6.8.2.4. South Africa Lung Adenocarcinoma Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)

6.8.3. Saudi Arabia

6.8.3.1. Key Country Dynamics

6.8.3.2. Regulatory Framework

6.8.3.3. Competitive Insights

6.8.3.4. Saudi Arabia Lung Adenocarcinoma Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)

6.8.4. UAE

6.8.4.1. Key Country Dynamics

6.8.4.2. Regulatory Framework

6.8.4.3. Competitive Insights

6.8.4.4. UAE Lung Adenocarcinoma Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)

6.8.5. Kuwait

6.8.5.1. Key Country Dynamics

6.8.5.2. Regulatory Framework

6.8.5.3. Competitive Insights

6.8.5.4. Kuwait Lung Adenocarcinoma Treatment Market Estimates And Forecasts,
2018 - 2030 (USD Million)

CHAPTER 7. COMPETITIVE LANDSCAPE

7.1. Participant Overview

7.2. Company Market Position Analysis

7.3. Company Categorization

7.4. Strategy Mapping

7.5. Company Profiles/Listing

7.5.1. Pfizer Inc.

7.5.1.1. Overview

7.5.1.2. Financial Performance

7.5.1.3. Product Benchmarking

7.5.1.4. Strategic Initiatives

7.5.2. AstraZeneca

7.5.2.1. Overview

7.5.2.2. Financial Performance

7.5.2.3. Product Benchmarking

7.5.2.4. Strategic Initiatives

7.5.3. Bristol-Myers Squibb Company

7.5.3.1. Overview

7.5.3.2. Financial Performance

7.5.3.3. Product Benchmarking

7.5.3.4. Strategic Initiatives

7.5.4. Eli Lilly and Company

7.5.4.1. Overview

7.5.4.2. Financial Performance

7.5.4.3. Product Benchmarking

7.5.4.4. Strategic Initiatives

7.5.5. Boehringer Ingelheim International GmbH

7.5.5.1. Overview

7.5.5.2. Financial Performance

7.5.5.3. Product Benchmarking

7.5.5.4. Strategic Initiatives

7.5.6. Novartis AG

7.5.6.1. Overview

7.5.6.2. Financial Performance

- 7.5.6.3. Product Benchmarking
- 7.5.6.4. Strategic Initiatives
- 7.5.7. Merck KGaA (EMD Serono)
 - 7.5.7.1. Overview
 - 7.5.7.2. Financial Performance
 - 7.5.7.3. Product Benchmarking
 - 7.5.7.4. Strategic Initiatives
- 7.5.8. AbbVie Inc.
 - 7.5.8.1. Overview
 - 7.5.8.2. Financial Performance
 - 7.5.8.3. Product Benchmarking
 - 7.5.8.4. Strategic Initiatives
- 7.5.9. Astellas Pharma Inc.
 - 7.5.9.1. Overview
 - 7.5.9.2. Financial Performance
 - 7.5.9.3. Product Benchmarking
 - 7.5.9.4. Strategic Initiatives
- 7.5.10. F. Hoffmann-La Roche Ltd
 - 7.5.10.1. Overview
 - 7.5.10.2. Financial Performance
 - 7.5.10.3. Product Benchmarking
 - 7.5.10.4. Strategic Initiatives

I would like to order

Product name: Lung Adenocarcinoma Treatment Market Size, Share & Trends Analysis Report By Treatment (Chemotherapy, Immunotherapy, Radiation Therapy), By End-use (Hospitals, Specialty Clinics), By Region (North America, Europe), And Segment Forecasts, 2025 - 2030

Product link: <https://marketpublishers.com/r/L5E47BD0C4CCEN.html>

Price: US\$ 5,950.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/L5E47BD0C4CCEN.html>